Total Payments
$256,405
2024 Payments
$31,699
Companies
22
Transactions
229
Medicare Patients
224
Medicare Billing
$35,376
Payment Breakdown by Category
Consulting$154,080 (60.1%)
Other$37,078 (14.5%)
Research$34,523 (13.5%)
Travel$26,136 (10.2%)
Food & Beverage$4,576 (1.8%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $154,080 | 73 | 60.1% |
| Unspecified | $34,523 | 34 | 13.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,523 | 18 | 11.9% |
| Travel and Lodging | $26,136 | 39 | 10.2% |
| Honoraria | $6,205 | 4 | 2.4% |
| Food and Beverage | $4,576 | 59 | 1.8% |
| Grant | $350.00 | 1 | 0.1% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$221,882
195 transactions
Research
$34,523
34 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $46,475 | 53 | $0 (2024) |
| F. Hoffmann-La Roche AG | $37,938 | 44 | $0 (2024) |
| AstraZeneca UK Limited | $27,824 | 10 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $26,380 | 18 | $0 (2024) |
| Chugai Pharmaceutical Co., Ltd. | $21,120 | 9 | $0 (2021) |
| PFIZER INC. | $15,021 | 12 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $14,250 | 8 | $0 (2021) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $12,284 | 11 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $8,123 | 12 | $0 (2024) |
| Seattle Genetics, Inc. | $7,338 | 10 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,699 | 22 | AstraZeneca Pharmaceuticals LP ($9,940) |
| 2023 | $36,487 | 18 | Daiichi Sankyo Inc. ($12,458) |
| 2022 | $23,237 | 24 | AstraZeneca UK Limited ($8,815) |
| 2021 | $37,004 | 19 | AstraZeneca UK Limited ($10,789) |
| 2020 | $38,863 | 32 | F. Hoffmann-La Roche AG ($15,215) |
| 2019 | $29,228 | 39 | E.R. Squibb & Sons, L.L.C. ($8,073) |
| 2018 | $40,426 | 42 | Chugai Pharmaceutical Co., Ltd. ($18,590) |
| 2017 | $19,462 | 33 | Amgen Inc. ($5,390) |
All Payment Transactions
229 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,794.83 | Research |
| Study: Ph I Dose escalation w GDC 0077 in breast cancer | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,377.29 | Research |
| Study: Ph I Dose escalation w GDC 0077 in breast cancer | ||||||
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 12/04/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 11/27/2024 | PFIZER INC. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 10/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 09/27/2024 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $805.00 | General |
| 08/22/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 08/22/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 07/17/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| 05/08/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| 04/01/2024 | F. Hoffmann-La Roche AG | Herceptin (Biological), Kadcyla, Perjeta | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| Category: BioOncology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,378.88 | Research |
| Study: Ph I Dose escalation w GDC 0077 in breast cancer | ||||||
| 02/23/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $350.00 | General |
| 01/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2024 | PFIZER INC. | TUKYSA (Drug) | Honoraria | Cash or cash equivalent | $1,400.00 | General |
| Category: Oncology | ||||||
| 01/01/2024 | F. Hoffmann-La Roche AG | Herceptin (Biological), Kadcyla, Perjeta | Consulting Fee | Cash or cash equivalent | $380.00 | General |
| Category: BioOncology | ||||||
| 12/20/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,883.75 | General |
| 12/18/2023 | AstraZeneca UK Limited | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $5,137.50 | General |
| Category: Oncology | ||||||
| 12/18/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph I Dose escalation w GDC 0077 in breast cancer | F. Hoffmann-La Roche AG | $6,707 | 6 |
| A randomized, Multicenter, Phase III Open-Label study of the efficacy and safety of Trastuzumab-MCC-DM1 vs. Capecitabine Lapatinib in patients with HER2-Positive locally advanced or metastic breast cancer who have received prior Trastuzumab-based therapy. | F. Hoffmann-La Roche AG | $5,814 | 1 |
| CLEE011F2301 | Novartis Pharma AG | $4,640 | 1 |
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER | F. Hoffmann-La Roche AG | $3,655 | 4 |
| A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY | F. Hoffmann-La Roche AG | $2,381 | 3 |
| An Open-Label Phase I Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Administered Alone and in Combination with Endocrine and Targeted Therapies in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer | F. Hoffmann-La Roche AG | $2,332 | 7 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,190 | 4 |
| AN OPEN-LABEL PHASE I DOSE ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0077 ADMINISTERED ALONE AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CANCER | F. Hoffmann-La Roche AG | $1,368 | 2 |
| GDC 0032 HER2 HR phase III LIP phase III | F. Hoffmann-La Roche AG | $956.23 | 1 |
| A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer | F. Hoffmann-La Roche AG | $271.53 | 1 |
| Chemo trastuzumab vs chemo trastuzumab pertuzumab | F. Hoffmann-La Roche AG | $169.64 | 1 |
| Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | Seattle Genetics, Inc. | $60.05 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 12 | 18 | $8,910 | $2,130 |
| 2022 | 1 | 11 | 11 | $4,389 | $601.02 |
| 2021 | 4 | 104 | 190 | $89,079 | $19,468 |
| 2020 | 5 | 97 | 168 | $54,525 | $13,176 |
Total Patients
224
Total Services
387
Medicare Billing
$35,376
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 12 | 18 | $8,910 | $2,130 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 11 | $4,389 | $601.02 | 13.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 31 | 78 | $47,364 | $9,922 | 20.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 47 | 78 | $26,322 | $6,042 | 23.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $9,833 | $2,261 | 23.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 20 | $5,560 | $1,244 | 22.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 40 | 79 | $21,361 | $5,072 | 23.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $12,282 | $3,133 | 25.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 13 | 39 | $9,438 | $2,481 | 26.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 18 | $8,760 | $1,774 | 20.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 11 | 11 | $2,684 | $715.90 | 26.7% |
About Ian Krop, MD PHD
Ian Krop, MD PHD is a Medical Oncology healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033187455.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ian Krop, MD PHD has received a total of $256,405 in payments from pharmaceutical and medical device companies, with $31,699 received in 2024. These payments were reported across 229 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($154,080).
As a Medicare-enrolled provider, Krop has provided services to 224 Medicare beneficiaries, totaling 387 services with total Medicare billing of $35,376. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New Haven, CT
- Active Since 03/10/2006
- Last Updated 07/26/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1033187455
Products in Payments
- Herceptin (Biological) $26,801
- Enhertu (Drug) $25,849
- Non-Covered Product (Drug) $15,600
- Kadcyla (Biological) $12,976
- KEYTRUDA (Biological) $12,500
- ENHERTU (Biological) $10,735
- Lonsurf (Drug) $5,901
- XTANDI (Drug) $5,290
- KISQALI (Drug) $5,282
- PIQRAY (Drug) $5,003
- LEE011F_KISQALI_ONCOLOGY (Drug) $4,640
- LIV1A (Biological) $3,140
- ENHERTU (Drug) $2,800
- TUKYSA (Drug) $2,700
- MARGENZA (Drug) $1,500
- Perjeta (Biological) $1,388
- Turalio (Drug) $67.00
- Nerlynx (Drug) $35.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New Haven
Mandar Muzumdar, Md, MD
Medical Oncology — Payments: $741,000
Medical Oncology $741,000
Francine Foss, Md, MD
Medical Oncology — Payments: $280,568
Medical Oncology $280,568
Maryam Lustberg, M.d, M.D
Medical Oncology — Payments: $252,571
Medical Oncology $252,571
Lajos Pusztai, M.d., D.phil, M.D., D.PHIL
Medical Oncology — Payments: $184,479
Medical Oncology $184,479
Anne Chiang, Md, MD
Medical Oncology — Payments: $151,212
Medical Oncology $151,212
Dr. Eric Winer, M.d, M.D
Medical Oncology — Payments: $139,969
Medical Oncology $139,969